Retour
45
Fourchette du Jour
68,85 €
70,50 €
Fourchette 52 Semaines
67,56 €
109,50 €
Volume
8 603 601
Moyenne 50J / 200J
80,41 €
/
95,75 €
Clôture Précédente
69,48 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 35,8 | 0,4 |
| P/B | 4,3 | 2,9 |
| ROE % | 12,6 | 3,7 |
| Net Margin % | 14,4 | 3,8 |
| Rev Growth 5Y % | 14,0 | 10,0 |
| D/E | 0,5 | 0,2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 |
Morano Susan E
Director
|
grant | 24 | — | — |
| Mar 2, 2026 |
Pegus Cheryl
Director
|
grant | 24 | — | — |
| Mar 1, 2026 |
Woodworth Emily
SVP, Global Controller and CAO
|
other | 2 048 | — | — |
| Nov 28, 2025 |
O'Sullivan Miriam
SVP, Chief HR Officer
|
other | 260 | — | — |
| Nov 14, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 9 610 | — | — |
| Nov 12, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 690 | — | — |
| Aug 1, 2025 |
LUDWIG EDWARD J
Director
|
other | 500 | — | — |
| Jul 29, 2025 |
FUJIMORI YOSHIAKI
Director
|
sell | 2 901 | 106,99 € | 310 378 € |
| Jul 1, 2025 |
Monson Jonathan
EVP and CFO
|
grant | 30 523 | — | — |
| May 29, 2025 |
LUDWIG EDWARD J
Director
|
sell | 4 000 | 104,59 € | 418 368 € |
| May 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4 826 | 106,42 € | 513 583 € |
| May 8, 2025 |
Habiger David C
Director
|
grant | 2 081 | — | — |
| May 8, 2025 |
WICHMANN DAVID S
Director
|
grant | 2 081 | — | — |
| May 8, 2025 |
Mega Jessica L
Director
|
grant | 2 081 | — | — |
| May 8, 2025 |
Zane Ellen M
Director
|
grant | 2 081 | — | — |
| May 8, 2025 |
LUDWIG EDWARD J
Director
|
grant | 2 081 | — | — |
| May 5, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
sell | 4 572 | 104,54 € | 477 957 € |
| May 2, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
other | 10 326 | — | — |
| May 2, 2025 |
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
|
other | 5 221 | — | — |
| Apr 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4 826 | 95,09 € | 458 904 € |
Points Clés
Revenue grew 13,99% annually over 5 years — strong growth
Earnings grew 55,66% over the past year
ROE of 12,55% — decent returns on equity
Generating 3,66B in free cash flow
P/E of 35,76 — premium valuation
PEG of 0,88 suggests growth is underpriced
Croissance
Revenue Growth (5Y)
13,99%
Revenue (1Y)19,87%
Earnings (1Y)55,66%
FCF Growth (3Y)46,56%
Qualité
Return on Equity
12,55%
ROIC8,13%
Net Margin14,38%
Op. Margin19,78%
Sécurité
Debt / Equity
0,51
Current Ratio1,62
Interest Coverage11,38
Valorisation
P/E Ratio
35,76
P/B Ratio4,26
EV/EBITDA28,60
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,87% | Revenue Growth (3Y) | 18,73% |
| Earnings Growth (1Y) | 55,66% | Earnings Growth (3Y) | 34,60% |
| Revenue Growth (5Y) | 13,99% | Earnings Growth (5Y) | 29,07% |
| Profitability | |||
| Revenue (TTM) | 20,07B | Net Income (TTM) | 2,89B |
| ROE | 12,55% | ROA | 6,61% |
| Gross Margin | 69,01% | Operating Margin | 19,78% |
| Net Margin | 14,38% | Free Cash Flow (TTM) | 3,66B |
| ROIC | 8,13% | FCF Growth (3Y) | 46,56% |
| Safety | |||
| Debt / Equity | 0,51 | Current Ratio | 1,62 |
| Interest Coverage | 11,38 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 35,76 | P/B Ratio | 4,26 |
| P/S Ratio | 5,14 | PEG Ratio | 0,88 |
| EV/EBITDA | 28,60 | Dividend Yield | 0,00% |
| Market Cap | 103,19B | Enterprise Value | 113,56B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 20,07B | 16,75B | 14,24B | 12,68B | 11,89B |
| Net Income | 2,89B | 1,85B | 1,59B | 698,00M | 1,04B |
| EPS (Diluted) | 1,94 | 1,25 | 1,07 | 0,45 | 0,69 |
| Gross Profit | 13,85B | 10,27B | 8,83B | 7,71B | 7,46B |
| Operating Income | 3,97B | 2,64B | 2,18B | 1,82B | 1,92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 43,67B | 39,40B | 35,14B | 32,47B | 32,23B |
| Total Liabilities | 19,20B | 17,39B | 15,61B | 14,90B | 15,61B |
| Shareholders' Equity | 24,23B | 21,77B | 19,28B | 17,57B | 16,62B |
| Total Debt | 12,42B | 11,15B | 9,49B | 9,28B | 9,45B |
| Cash & Equivalents | 2,05B | 414,00M | 865,00M | 928,00M | 1,93B |
| Current Assets | 8,79B | 6,92B | 6,51B | 5,76B | 6,32B |
| Current Liabilities | 5,44B | 6,40B | 4,93B | 3,80B | 4,27B |
Scores de Stratégies
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#521 of 1024
Activité Récente
Entré
Cash Flow Compounder
Mar 24, 2026